Cabozantinib
- Catalog NO.:A841013
- CAS No. : 849217-68-1
- Molecular Formula:C28H24FN3O5
- Molecular Weight: 501.50
1. Please click the
![](/usr/uploads/3/201903/xunpan.png.png)
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 849217-68-1 | Appearance | Off-white powder |
Catalog Number | A841013 | MDL Number | MFCD20926324 |
Molecular Formula | C28H24FN3O5 | Molecular Weight | 501.50 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | XL184; BMS 907351;N1'-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram |
![]() |
||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H320-H335 | Class | |
Precautionary Statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 | Packing Group |
Description
Cabozantinib, also known as XL-184 or BMS-907351, is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several tyrosine receptor kinases. Specifically, cabozantinib appears to have a strong affinity for the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in inhibition of tumor growth and angiogenesis, and tumor regression. Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. |